- Title
- MiToS and King’s staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial
- Creators
- Paulos Gebrehiwet - Cytokinetics (United States)Lisa Meng - Cytokinetics (United States)Stacy A. Rudnicki - Cytokinetics (United States)Phil Sarocco - Cytokinetics (United States)Jenny Wei - Cytokinetics (United States)Andrew A. Wolff - Cytokinetics (United States)Adriano Chiò - University of TurinJinsy A. Andrews - The Neurological InstituteAngela Genge - Montreal Neurological Institute and HospitalCarlayne E. Jackson - The University of Texas Health Science Center at San AntonioNoah Lechtzin - Johns Hopkins UniversityTimothy M. Miller - Washington University in St. LouisJeremy M. Shefner - Barrow Neurological Institute
- Publication Details
- Amyotrophic lateral sclerosis and frontotemporal degeneration, Vol.24(3-4), pp.304-310
- Number of pages
- 7
- Grant note
- Cytokinetics (http://data.elsevier.com/vocabulary/SciValFunders/100014941) Astellas Pharma (http://data.elsevier.com/vocabulary/SciValFunders/501100004948)
- Identifiers
- 991006262199202656
- Academic Unit
- Neurology
- Language
- English
- Resource Type
- Journal article
Journal article
MiToS and King’s staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial
Amyotrophic lateral sclerosis and frontotemporal degeneration, Vol.24(3-4), pp.304-310
04/03/2023
PMID: 36503310
Metrics
1 Record Views